Q2 EPS Forecast for Anavex Life Sciences Boosted by Analyst

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Investment analysts at HC Wainwright increased their Q2 2026 earnings estimates for shares of Anavex Life Sciences in a note issued to investors on Tuesday, February 10th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.11). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.33) EPS.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04.

AVXL has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Anavex Life Sciences in a report on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and set a $24.00 price objective on shares of Anavex Life Sciences in a research report on Monday. Finally, Jones Trading lowered shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Anavex Life Sciences presently has a consensus rating of “Hold” and an average target price of $22.00.

Anavex Life Sciences Stock Down 2.0%

NASDAQ AVXL opened at $3.88 on Thursday. The firm has a market cap of $359.56 million, a price-to-earnings ratio of -8.43 and a beta of 1.21. The business has a 50-day moving average price of $4.28 and a 200-day moving average price of $6.95. Anavex Life Sciences has a twelve month low of $2.86 and a twelve month high of $13.99.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Anavex Life Sciences by 10.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,525 shares of the biotechnology company’s stock valued at $434,000 after purchasing an additional 4,869 shares in the last quarter. Stratos Wealth Partners LTD. bought a new stake in shares of Anavex Life Sciences in the 2nd quarter worth about $245,000. 180 Wealth Advisors LLC increased its holdings in shares of Anavex Life Sciences by 213.4% in the 2nd quarter. 180 Wealth Advisors LLC now owns 44,050 shares of the biotechnology company’s stock worth $406,000 after buying an additional 29,995 shares during the last quarter. Atria Investments Inc raised its position in shares of Anavex Life Sciences by 18.2% during the 2nd quarter. Atria Investments Inc now owns 22,110 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 3,406 shares in the last quarter. Finally, Kovack Advisors Inc. bought a new position in shares of Anavex Life Sciences in the 2nd quarter valued at about $93,000. 31.55% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $20.00 price target (implying large upside) and published FY2027 and quarterly EPS forecasts that are less negative than consensus (FY2027 -$0.55 vs consensus -$0.69) — supportive for sentiment and valuation expectations. MarketBeat – AVXL HC Wainwright Report
• Positive Sentiment: Analysis pieces argue Anavex may be approaching cash?flow breakeven, a narrative investors view positively for a small biotech with ongoing R&D spend. Breakeven On The Horizon For Anavex Life Sciences (Yahoo)
• Neutral Sentiment: The company’s Q1 2026 earnings call transcript is available for investors wanting primary detail on recent results and management commentary; it may clarify near?term guidance but contains no single market?moving surprise. Q1 2026 Earnings Call Transcript (MSN)
• Neutral Sentiment: Short?interest reports show 0 shares and a days?to?cover of 0.0, but entries include NaN and appear to be data glitches — there is no clear evidence of new short pressure driving the move. (No linked source; reported in market data feed.)
• Negative Sentiment: A Seeking Alpha piece highlights a negative European regulator opinion on blarcamesine, Anavex’s lead asset, calling the program into “regulatory purgatory” — that regulatory uncertainty is the most direct near?term negative for valuation and explains downward pressure. Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory (Seeking Alpha)

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical?stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma?1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2?73), is a small?molecule activator of the sigma?1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.